Galux, a South Korean biotech company at the forefront of AI-driven protein therapeutics discovery, has announced a research collaboration with Boehringer Ingelheim to explore the use of artificial intelligence in precision protein design for therapeutic development. The partnership aims to evaluate how AI can be applied to create purpose-built protein molecules that meet exact scientific and translational requirements—challenges often difficult to address with traditional methods. “Through this agreement, we aim to demonstrate that AI can go beyond predicting protein structures to actively designing molecules with specific, well-defined functions,” said Chaok Seok, CEO of Galux. “This is about moving from prediction to purposeful design—creating proteins that are precisely tailored to meet clear research and therapeutic goals.” The collaboration builds on Galux’s recent breakthroughs in de novo antibody design, where the company successfully identified novel antibodies with high binding affinity, target specificity, selectivity, structural accuracy, and stability across multiple therapeutic targets. These results have solidified GaluxDesign, the company’s AI platform, as one of the most advanced and experimentally validated systems for protein engineering. The initial phase of the partnership will focus on assessing the feasibility and potential of AI-driven protein design in selected cases, laying the groundwork for future, larger-scale research initiatives. The project brings together Galux’s cutting-edge AI technology with Boehringer Ingelheim’s deep expertise in drug development and translational science. “At Galux, we believe the future of medicine lies in the ability to design therapeutics with precision and intention,” Seok added. “This collaboration is a key step toward realizing that vision—uniting the power of AI with the rigor of biomedical research to unlock new possibilities in drug discovery.” Galux is redefining drug discovery by combining deep learning with the physical laws governing protein folding and molecular interactions. The company develops therapeutic proteins from scratch, enabling highly targeted and customizable solutions across a wide range of disease targets and therapeutic modalities. With a growing network of global partnerships and a strong foundation in experimental validation, Galux is leading a new era of rational, AI-powered drug development. For more information, visit galux.co.kr. Contact: Galux Nicole Noh [email protected]